CLBP’s Unmet Need and Why Existing Treatments Fall Short

Chronic low back pain — defined as back pain persisting beyond 12 weeks — is one of the most prevalent causes of disability and lost productivity worldwide, with US prevalence estimates ranging from 6.4% to 8.1% and European non-specific CLBP prevalence approaching 23%. The scale of the problem has driven substantial patent activity, yet the therapeutic toolkit remains inadequate: Pfizer’s own patent filings explicitly note that commonly used agents — NSAIDs, tricyclic antidepressants, muscle relaxants, and opioid analgesics — are “not fully effective in many patients” and carry risks including gastrointestinal bleeding, somnolence, and cognitive impairment.

The opioid crisis has intensified demand for mechanistically distinct, non-addictive analgesics. According to WHO, opioid dependence affects millions globally, and the clinical and regulatory pressure to offer alternatives has become a core driver of innovation in the CLBP space. The majority of CLBP cases lack a specific etiology, necessitating symptomatic rather than disease-modifying treatment strategies — a characteristic that has shaped both the patent landscape and the therapeutic hypotheses being pursued.

Genomic and biomarker research is beginning to illuminate why CLBP is so heterogeneous. A McGill University paper identifies CNS, musculoskeletal, and immune gene networks in back pain genome-wide association studies (GWAS), with equal neuronal and immunological contributions to pain susceptibility. The US Department of Veterans Affairs has filed patents disclosing diagnostic biomarker panels — including HTR2A, EDN1, PNOC (prepronociceptin), and CALCA — for pain state identification and pharmacogenomic-guided treatment selection. This genomic stratification infrastructure is increasingly viewed as a prerequisite for precision medicine approaches to CLBP.

Anti-NGF Antibodies: The Dominant Commercial Battlefield

Nerve growth factor (NGF) and its high-affinity receptor TrkA (NTRK1) are the most extensively patent-covered targets in the CLBP drug pipeline. NGF is upregulated in injured and inflamed tissue, where it drives sensitization of nociceptors in the dorsal root ganglion (DRG) and peripheral tissue — a cascade that sustains chronic pain long after the initial injury. Anti-NGF antibodies block NGF binding at both TrkA and the low-affinity receptor p75NTR, interrupting this sensitization mechanism at its source.

“Regeneron Pharmaceuticals holds at least 10 distinct patent filings across 9 jurisdictions covering fasinumab and anti-NGF compositions — framing the indication not only as pain relief but as opioid addiction prevention.”

Regeneron Pharmaceuticals holds the largest single anti-NGF patent portfolio in the surveyed dataset, with filings across US, WO, EP, AU, NZ, JP, CA, SG, MY, MX, BR, CO, and PH jurisdictions. The commercial and regulatory framing is notable: Regeneron’s patent claims explicitly cover “averting opioid addiction” by substituting NGF antibody therapy for opioids in moderate-to-severe LBP patients — a framing that broadens the indication claim and aligns with public health priorities. Fasinumab is named explicitly as a selective NGF blocker in these filings.

Pfizer holds parallel multi-jurisdictional patent families (WO, CA, US, JP) covering treatment of CLBP with anti-NGF antibodies, disclosing a specific tanezumab dose of approximately 10 mg every 8 weeks via subcutaneous injection. Tanezumab clinical trial data — including Brown et al. (J Pain 2012, Arthritis Rheum 2013) and Gimbel et al. (Pain 2014) — are cited within Pfizer’s OA patent as demonstrating “clinically meaningful improvements” in pain reduction, physical function, and Patient’s Global Assessment. Earlier foundational anti-NGF IP from Rinat Neuroscience (now part of Pfizer) covers use in post-surgical pain, rheumatoid arthritis pain, and osteoarthritis pain.

Additional anti-NGF IP comes from PanGenetics (Netherlands) and Abbott Research, whose filings describe anti-NGF/TrkA blocking antibodies for chronic pain with prolonged analgesic effect. The mechanistic rationale described across these filings is detailed: TrkA activation in primary sensory neurons (DRG) triggers release of glutamate, ATP, substance P, and CGRP — providing a rationale for the broad analgesic effect of anti-NGF agents that extends beyond simple peripheral blockade. Paradigm Biopharmaceuticals extends the approach to polysulfated polysaccharides that modulate both mature NGF and pro-NGF.

Beyond NGF: Second-Wave Targets and Novel Modalities

Eli Lilly’s dual TGF-alpha/epiregulin antibody approach represents a second-generation differentiation from the NGF axis, specifically targeting therapy-resistant chronic pain patients who have failed two or more prior analgesic regimens. TGF-alpha and epiregulin are both ligands of the EGFR pathway implicated in chronic pain signaling; the dual antibody addresses both nociceptive and neuropathic components of CLBP, with patents filed across WO, CA, AU, and JP jurisdictions between 2021 and 2025. This positions the asset to address a failure mode of the first generation of anti-NGF biologics — particularly relevant if safety concerns such as arthropathy signals restrict the anti-NGF addressable population.

TNF-alpha has attracted persistent interest as a CLBP pain mediator across two decades of patent activity. Early filings by A+ Science Invest AB and inventor Kjell Olmarker (2002, WO and AU) describe TNF inhibitors for LBP specifically attributed to local irritation of annulus-related nerve fibers by disc-derived substances — a disc-centric anti-inflammatory mechanism distinct from systemic inflammatory arthritis. More recently, MedImmune (AstraZeneca subsidiary) filed patents for bifunctional polypeptides co-targeting NGF and TNFα, with the rationale that combination provides superior pain control versus either agent alone in preclinical models. Immunomedics (Gilead subsidiary) has elaborated dosing regimens for such NGF/TNFα dual antagonists.

Small molecule and nucleic acid approaches are also gaining patent traction. Grünenthal GmbH has filed patents for substituted 2-oxy-quinoline-3-carboxamides as KCNQ2/3 (Kv7.2/7.3) modulators — voltage-gated potassium channels expressed in sensory neurons whose opening reduces neuronal excitability, offering a non-opioid analgesic mechanism. West China Hospital of Sichuan University has patented siRNA/shRNA nucleic acid drugs targeting NALCN (sodium leak channel, non-selective) for neuropathic and inflammatory chronic pain, formulated in liposomes, cationic polymer micelles, or AAV vectors, with claims of longer analgesic duration compared to small molecules. AnGes, Inc. (Japan/Canada) filed a patent for double-stranded oligonucleotide decoys binding NF-κB and STAT6 transcription factor DNA binding sites for intervertebral disc degeneration and spinal pain — targeting two inflammatory transcription factors simultaneously.

Non-pharmacological and cellular modalities are also represented. Mesoblast International disclosed methods using mesenchymal lineage precursor or stem cells (MLPSCs) to reduce pain and decrease opioid use in chronic pain patients, with claims for improved EQ-5D quality-of-life scores. Relievant Medsystems filed patents for AI-based patient selection systems using deep learning algorithms to predict favorable response to spinal neuromodulation procedures, including basivertebral nerve ablation, for CLBP stemming from vertebral bodies or endplates. Kyphon SARL holds earlier patents for chemical denervation agents targeting the basivertebral nerve specifically for chronic back pain. These device and cellular approaches reflect the broadening definition of the CLBP pipeline, consistent with the NIH HEAL Initiative’s multi-modal approach to non-opioid pain management.

Central Sensitization and the CNS-Targeting Opportunity

Central sensitization — in which sustained pain signaling is maintained by CNS neuronal changes rather than ongoing peripheral inflammation — is an underexploited mechanistic opportunity in the CLBP patent landscape. Medicon Pharmaceuticals holds active patents (CN, WO, 2025) covering sulindac phosphate (PS), a non-COX-inhibiting sulindac metabolite, for treatment of pain associated with central sensitization. The mechanistic claim is that PS acts directly on CNS neurons involved in sustained pain signaling, independently of the peripheral anti-inflammatory activity associated with conventional NSAIDs — a distinction that could allow PS to address pain phenotypes where existing agents fail.

Dopaminergic pathways are implicated in the transition from acute to chronic pain, and Apkarian Technologies LLC (linked to academic work from Northwestern University) has filed US, WO, and CA patents for combinations of dopaminergic agents (D1 or D2 receptor agonists) with analgesics at low dopaminergic-to-analgesic ratios to prevent this transition. One specific combination studied is levodopa/carbidopa plus naproxen (LDP+NPX), with a 72-participant double-blind, placebo-controlled trial cited within the patent text reporting superior efficacy in females — defined as greater than 80% pain relief — over 12 weeks in subacute back pain patients at risk for chronification. This approach is conceptually distinct from treating established CLBP: it targets a unique window in the pain trajectory to interrupt chronification before it occurs.

The University of California has filed a WO patent (2022) for NAAA (N-acylethanolamine acid amidase) inhibition as a mechanism to halt consolidation of chronic pain states, differentiating this approach from gabapentin, ketamine, ketoprofen, and morphine, which reportedly failed in the same preclinical model. NuvaMid SA has filed a US patent (2023) for nicotinamide mononucleotide (NMN) as a treatment and prevention strategy for chronic lumbalgia, representing a metabolic and mitochondrial approach to CLBP that is mechanistically novel within this dataset. Genomic biomarker research from McGill University — identifying equal neuronal and immunological contributions to pain susceptibility via GWAS — provides the scientific foundation for patient stratification tools that could eventually match centralized pain phenotypes to CNS-targeted therapies, a convergence that OECD health innovation frameworks increasingly recognize as essential for precision pain medicine.

A 2018 systematic review from the University of Nottingham (8 RCTs, n=615) demonstrated short-term pain benefit for pain neuroscience education in CLBP, with a weighted mean difference of 0.73 (95% CI reported). A non-randomized controlled clinical trial measuring TNFα, IL-1β, IL-6, IL-2, and IFN-γ production before and after six spinal manipulative therapy (SMT) sessions over two weeks provided clinical biomarker data for inflammatory modulation by a non-pharmacological intervention, suggesting that inflammatory cytokines remain measurable and modifiable targets even in established CLBP. These clinical signals complement the mechanistic IP and suggest that central sensitization phenotyping may become a practical patient selection tool.

Combination Strategies, Precision Medicine, and Emerging Directions

The CLBP pipeline is converging on combination and precision medicine strategies that go beyond single-target monotherapy. The most commercially advanced combination signal involves bispecific NGF/TNFα dual antagonism: MedImmune and Immunomedics patent filings describe bifunctional polypeptides co-targeting NGF and TNFα, with the rationale that heterogeneous pain etiology in CLBP — where both neurotrophic and inflammatory pathways are simultaneously active — requires multi-target blockade for superior analgesia.

Patient stratification is emerging as an IP-protectable asset adjacent to the therapeutic pipeline. Regeneron’s 2025 OA proteomics patent introduces a weighted protein expression risk score to predict which patients are most likely to respond to NGF antagonist treatment versus progressing to total joint replacement — a precision medicine approach that signals could be extended to CLBP patient selection. The US Department of Veterans Affairs holds patents disclosing diagnostic biomarker panels (HTR2A, EDN1, PNOC, CALCA) for pain state identification and pharmacogenomic-guided treatment selection. AI-guided neuromodulation patient selection from Relievant Medsystems reflects growing convergence of digital health and interventional pain management, consistent with the trajectory described by WIPO‘s Technology Trends reporting on AI in health.

“Framing CLBP agents within opioid-reduction narratives appears to be an active IP and commercial positioning strategy explicitly embedded in multiple Regeneron patent claims — covering ‘averting opioid addiction’ as a distinct indication.”

Cannabinoid-based approaches are attracting increasing commercial patent activity. Vertanical GmbH (WO, 2025) filed a patent for a composition containing delta-9-tetrahydrocannabinol (THC) combined with alpha-bisabolol, guaiol, and beta-caryophyllene for treatment of CLBP and chronic non-specific LBP. Johns Hopkins University (China filing, 2025) filed patents for cannabinoid-dendrimer conjugates targeting CB1/CB2 receptors on neurons and activated microglia for chronic and neuropathic pain — addressing CNS delivery limitations of conventional cannabinoid formulations. An observational study (n=35) of ultra-micronized palmitoylethanolamide (Normast) as add-on to tapentadol/pregabalin in failed back surgery syndrome reported pain improvement on VAS at 1, 2, and 3 months, adding clinical context to the endocannabinoid-adjacent approach.

Opioid sparing is explicitly embedded as a commercial positioning strategy across multiple patent families: Regeneron’s “averting opioid addiction” framing, Mesoblast’s MLPSC opioid-reduction claims, and the broader narrative that non-opioid CLBP agents can be positioned for payer and regulatory advantage by reducing opioid dependence risk. IP strategists should monitor continuation filings and patient stratification claims as differentiating IP in this space, particularly as the FDA‘s non-opioid analgesic development guidance continues to evolve. Drug developers focusing on centralized pain phenotyping tools and matched therapeutics could occupy relatively uncontested IP space — a strategic opportunity that the current patent landscape suggests remains largely open.